HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Combination chemotherapy with vinblastine, ifosfamide and cisplatin in bulky seminoma.

Abstract
Since 1982, 24 patients with bulky seminoma were treated with the VIP-regimen consisting of vinblastine 6 mg/m2 days 1+2, ifosfamide 1.5 g/m2 days 1-5, cisplatin 20 mg/m2 days 1-5. One patient showed primary progression, another patient partial remission, and one patient died during the first cycle. All the other patients had complete remission (21/24 = 87%), which was documented histologically in 9 patients. One patient relapsed but obtained complete remission after repeated treatment. Thus 21 patients are currently living without disease after a median observation time of 30+ months. Bone marrow toxicity was severe, leading to dose reduction in more than 50% of the patients. No other severe side effects were observed. We conclude that the regimen is highly effective in bulky seminoma. Reduction of the vinblastine dose is recommended because of bone marrow toxicity.
AuthorsC Clemm, R Hartenstein, N Willich, G Ledderose, W Wilmanns
JournalActa oncologica (Stockholm, Sweden) (Acta Oncol) Vol. 28 Issue 2 Pg. 231-5 ( 1989) ISSN: 0284-186X [Print] England
PMID2736112 (Publication Type: Journal Article)
Chemical References
  • Vinblastine
  • Cisplatin
  • Ifosfamide
Topics
  • Adult
  • Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
  • Cisplatin (administration & dosage)
  • Dysgerminoma (drug therapy, pathology)
  • Humans
  • Ifosfamide (administration & dosage)
  • Middle Aged
  • Neoplasm Staging
  • Remission Induction
  • Vinblastine (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: